SCHEMBL2967245

SCHEMBL2967245

CCCN1CCC(N2CCC(n3nc(-c4ccc5c(ccn5Cc5ccccc5Cl)c4)c4c(N)ncnc43)CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 10/20 0.53
▸ EGFR P00533 8/20 0.53
▸ KDR P35968 4/20 0.53
▸ PIK3CD O00329 3/20 0.53
▸ PIK3CA P42336 3/20 0.53
▸ PIK3CB P42338 3/20 0.53
▸ PIK3CG P48736 3/20 0.53
▸ PRKDC P78527 3/20 0.53
▸ ABL1 P00519 2/20 0.53
▸ HCK P08631 2/20 0.53
▸ MTOR P42345 2/20 0.53
▸ EPHB4 P54760 2/20 0.53
▸ IGF1R P08069 9/20 0.51
▸ ERBB2 P04626 6/20 0.51
▸ LCK P06239 4/20 0.49
▸ CSK P41240 2/20 0.49
▸ ERBB3 P21860 3/20 0.48
▸ ERBB4 Q15303 3/20 0.48
▸ PI4KB Q9UBF8 1/20 0.46
▸ TEK Q02763 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2966218 0.94 SRC (0.57) SRCEGFRKDRPIK3CDPIK3CA
SCHEMBL2956089 0.93 SRC (0.51) SRCEGFRKDRPIK3CDPIK3CA
SCHEMBL2966182 0.93 SRC (0.56) SRCEGFRKDRPIK3CDPIK3CA
SCHEMBL2961198 0.93 EGFR (0.56) SRCEGFRKDRPIK3CDPIK3CA
SCHEMBL2958770 0.91 EGFR (0.51) SRCEGFRKDRPIK3CDPIK3CA
SCHEMBL2961978 0.90 SRC (0.59) SRCEGFRKDRPIK3CDPIK3CA
SCHEMBL2960266 0.90 IGF1R (0.56) SRCEGFRKDRPIK3CDPIK3CA
SCHEMBL2960030 0.89 IGF1R (0.57) SRCEGFRKDRPIK3CDPIK3CA
SCHEMBL2956065 0.89 IGF1R (0.53) SRCEGFRKDRPIK3CDPIK3CA
SCHEMBL2958145 0.89 IGF1R (0.53) SRCEGFRKDRPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP claimed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US claimed
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 SRC 106/4885EGFR 591/4885KDR 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback